摘要
目的 建立人肺腺癌多药耐药细胞系。方法 以顺铂为诱导药物 ,人肺腺癌细胞系SPC A 1为诱导对象 ,采用大剂量冲击与逐步增加剂量相结合的方法 ,诱导建立人肺腺癌多药耐药细胞系SPC A 1/CDDP ;MTT法测定药物敏感性 ,透射和扫描电镜观察形态变化 ,常规染色体检测分析染色体变化。结果 用 192d建成人肺腺癌多药耐药细胞系SPC A 1/CDDP ,它对顺铂的耐药指数为 11.2 ,对顺铂、5 氟尿嘧啶、丝裂霉素、长春新碱和足叶乙甙等药物有不同程度的耐药性 ,但对羟基喜树碱无耐药性 ,电镜观察可见SPC A 1/CDDP细胞胞核不规则 ,较大 ,有丰富的微绒毛。结论 本研究建立了稳定的人肺腺癌多药耐药细胞系 (SPC A 1/CDDP) ,可应用于下游实验。
Objective To establish a multidrug resistance cell line from human lung adenocarcinoma. Methods The human lung adenocarcinoma cell line SPC A 1 was exposed to cisplatin of a high and then increasing concentration for 192 d to establish multidrug resistance cell line (SPC A 1/CDDP). The relative resistance was tested with MTT assay. The morphology of the cells was observed with transmission and scanning electron microscopy and the chromosome of them was analyzed with Giemsa stained specimens. Results The resistance index of SPC A 1/CDDP cells to cisplatin was 11.2 and the cells showed various cross resistance to 5 Fu, doxorubicin, mitomycin, vincristine and etoposide, but not to hydroxycamptothecine. Electron microscopy showed the cells with irregular and enlarged nuclei and abundant microvilli. Conclusion A multidrug resistance cell line (SPC A 1/CDDP) from human lung adenocarcinoma is established. It can be used to downstream experiment.
出处
《第三军医大学学报》
CAS
CSCD
北大核心
2001年第2期135-137,共3页
Journal of Third Military Medical University
基金
第三军医大学疾病基因基金资助
重庆市卫生局医学科研资助项目!( 0 0 2 0 0 1)
